Trials / Sponsors / Heidelberg Pharma AG

Heidelberg Pharma AG

Industry · 9 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Recruiting	Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Multiple Myeloma, Plasma Cell Disorder	Phase 1 / Phase 2	2022-02-07
Withdrawn	REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT Renal Cell Carcinoma, Kidney Cancer	Phase 3	2017-12-01
Terminated	Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours Advanced Solid Tumours	Phase 1	2013-07-01
Terminated	Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Pat Advanced Solid Tumours	Phase 1 / Phase 2	2012-03-01
Completed	Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastat Metastatic Breast Cancer	Phase 2	2008-07-01
Completed	Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody Renal Cell Carcinoma, Kidney Cancer	Phase 3	2008-03-01
Completed	Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Pancreatic Cancer	Phase 2	2007-04-01
Completed	Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kid Kidney Cancer	Phase 3	2004-07-01
Completed	Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignanci Advanced Malignancies	Phase 1	2004-05-01